IGF-1 LR3Growth Factor Analog PeptideSafety Rating 4/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 1mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| SomaChemsBest $/mgCOA ✓ · 3P | $47.99 | $47.99 | May 14, 2026 | Buy → |
| Guru PeptidesCOA unknown | $54.99 | $54.99 | May 16, 2026 | Buy → |
| Amino ClubCOA ✓ · 3P | $55.99 | $55.99 | May 14, 2026 | Buy → |
| Petratide ScienceCOA ✓ · 3P | $59.95 | $59.95 | May 14, 2026 | Buy → |
| Swiss ChemsCOA ✓ · 3P | $59.96 | $59.96 | Apr 17, 2026 | Buy → $25 off $100+·auto |
Overview
About IGF-1 LR3
Mechanism of action
Analogue of IGF-1 with arginine substitution at position 3 and N-terminal extension; binds IGF-1 receptors; promotes muscle cell hyperplasia and hypertrophy; inhibits apoptosis; enhances nutrient uptake.
Safety profile
Hypoglycemia (most significant risk), jaw/organ growth with high doses, insulin resistance, acromegaly risk, water retention, potential cancer promotion. · Potent growth factor; proven hypoglycemia risk; potential tumor promotion concern backed by mechanistic data
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops IGF-1 LR3 below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Active malignancy — IGF-1 is a potent growth factor with documented tumor-promoting activity in preclinical models.
Severe hypoglycemia history or type 1 diabetes — IGF-1 causes significant hypoglycemia.
Hypersensitivity to IGF-1 or benzyl alcohol.
Related pages
More on IGF-1 LR3
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- Long R3 modification (Arg substitution at position 3 + 13-aa N-terminal extension) reduces IGF-binding protein (IGFBP) affinity by >95%, extending half-life from ~10 min to 20–30 hours.
- Demonstrated superior anabolic potency vs native IGF-1 in dexamethasone-treated catabolic rat models, supporting use in muscle-wasting and recovery contexts.